单克隆抗体水平和对COVID-19的保护
Eva Stadler1, Martin T Burgess2, Timothy E Schlub3
1Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Nature communications
|July 28, 2023
概括
单克隆抗体 (mAb) 有效地预防了症状性SARS-CoV-2感染. 特定的mAb度提供50%的保护,有助于预测对新变种的有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
背景情况:
- 单克隆抗体 (mAb) 是有效的SARS-CoV-2预防和治疗.
- 了解剂量反应关系对于优化mAb使用至关重要.
研究的目的:
- 为了建模mAb的剂量反应关系,以预防症状性SARS-CoV-2感染.
- 建立一个预测工具mAb预防疗效对当前和新兴的SARS-CoV-2变种.
主要方法:
- 来自对mAb进行SARS-CoV-2预防的随机对照试验的综合数据.
- 在体内模拟的mAb度和随时间推移的COVID-19保护.
- 在mAb治疗和疫苗接种后保护中和化标的比较.
主要成果:
- 估计在mAb (95%CI:32-285) 的体外IC50的96倍时,对COVID-19的保护率为50%.
- 开发了一个模型来预测新的mAb和针对SARS-CoV-2变种的预防疗效.
- 在mAb和疫苗接种之间,在50%的保护度上没有发现显著差异,尽管统计能力有限.
结论:
- 确定的mAb剂量-反应关系是预测预防疗效的宝贵工具.
- mAb和疫苗接种显示了相似的保护位,表明了类似的免疫反应机制.
- 需要使用更大的样本大小进行进一步的研究,以确认观察到的非显著差异.
更多相关视频
09:57Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
12.0K
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
663
相关概念视频
01:31Hybridoma Technology
14.9K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.9K
00:42Cross-reactivity
31.3K
Overview
31.3K